RU2014134365A - Вакцины против clostridium difficile, включающие рекомбинантные токсины - Google Patents
Вакцины против clostridium difficile, включающие рекомбинантные токсины Download PDFInfo
- Publication number
- RU2014134365A RU2014134365A RU2014134365A RU2014134365A RU2014134365A RU 2014134365 A RU2014134365 A RU 2014134365A RU 2014134365 A RU2014134365 A RU 2014134365A RU 2014134365 A RU2014134365 A RU 2014134365A RU 2014134365 A RU2014134365 A RU 2014134365A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- seq
- tcda
- tcdb
- difficile
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 15
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 108700012359 toxins Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract 54
- 230000035772 mutation Effects 0.000 claims abstract 15
- 230000002163 immunogen Effects 0.000 claims abstract 10
- 239000002773 nucleotide Substances 0.000 claims abstract 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 241000238631 Hexapoda Species 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 230000001131 transforming effect Effects 0.000 claims abstract 4
- 241000701447 unidentified baculovirus Species 0.000 claims abstract 4
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims abstract 3
- 101710182223 Toxin B Proteins 0.000 claims abstract 3
- 101710182532 Toxin a Proteins 0.000 claims abstract 3
- 239000002671 adjuvant Substances 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract 2
- 102220488184 Olfactory receptor 2A12_Y67A_mutation Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 102220485325 ATP-dependent DNA/RNA helicase DHX36_Y69A_mutation Human genes 0.000 claims 2
- 102220475348 Junctional protein associated with coronary artery disease_R255A_mutation Human genes 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591631P | 2012-01-27 | 2012-01-27 | |
| US61/591,631 | 2012-01-27 | ||
| US201261596419P | 2012-02-08 | 2012-02-08 | |
| US61/596,419 | 2012-02-08 | ||
| US201261703754P | 2012-09-20 | 2012-09-20 | |
| US61/703,754 | 2012-09-20 | ||
| PCT/US2013/023189 WO2013112867A1 (en) | 2012-01-27 | 2013-01-25 | Vaccines against clostridium difficile comprising recombinant toxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014134365A true RU2014134365A (ru) | 2016-03-20 |
Family
ID=48873956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014134365A RU2014134365A (ru) | 2012-01-27 | 2013-01-25 | Вакцины против clostridium difficile, включающие рекомбинантные токсины |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9388394B2 (OSRAM) |
| EP (1) | EP2807186A4 (OSRAM) |
| JP (2) | JP2015506948A (OSRAM) |
| KR (1) | KR20140117433A (OSRAM) |
| CN (1) | CN104039816B (OSRAM) |
| AR (1) | AR089797A1 (OSRAM) |
| AU (1) | AU2013211973B2 (OSRAM) |
| BR (1) | BR112014018432A8 (OSRAM) |
| CA (1) | CA2856443A1 (OSRAM) |
| IN (1) | IN2014CN04187A (OSRAM) |
| MX (1) | MX351074B (OSRAM) |
| RU (1) | RU2014134365A (OSRAM) |
| TW (1) | TW201335178A (OSRAM) |
| WO (1) | WO2013112867A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| CN103974718A (zh) * | 2011-12-08 | 2014-08-06 | 诺华股份有限公司 | 基于艰难梭菌毒素的疫苗 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JP2016518374A (ja) * | 2013-04-22 | 2016-06-23 | ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ | クロストリジウム・ディフィシルワクチン及び使用方法 |
| WO2014197651A1 (en) * | 2013-06-05 | 2014-12-11 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| CN105611942A (zh) | 2013-06-14 | 2016-05-25 | 圣诺菲·帕斯图尔公司 | 针对艰难梭菌免疫的组合物和方法 |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| JP2017212882A (ja) * | 2014-10-10 | 2017-12-07 | 学校法人 名城大学 | アセチルエステラーゼ及びその利用 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3294330A1 (en) | 2015-05-15 | 2018-03-21 | Sanofi Pasteur, Inc. | Methods for immunizing against clostridium difficile |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| AU2017227978B2 (en) | 2016-03-02 | 2022-03-10 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2019007012A (es) * | 2016-12-14 | 2019-11-28 | Merck Sharp & Dohme | Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile. |
| US10668140B2 (en) | 2017-02-24 | 2020-06-02 | University Of South Floirida | Non-toxigenic Clostridium difficile spores for use in oral vaccination |
| EP3595709A4 (en) * | 2017-03-15 | 2020-12-23 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE |
| US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
| MX388528B (es) | 2017-06-09 | 2025-03-20 | Hipra Scient S L U | Vacuna que comprende toxoides de clostridium. |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| ES2930237T3 (es) | 2017-07-06 | 2022-12-09 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| WO2020078420A1 (en) * | 2018-10-17 | 2020-04-23 | Eternity Biomedical Laboratories, Inc. | Immunogenic preparations and methods against clostridium difficile infection |
| CN110041437B (zh) * | 2019-04-29 | 2020-12-25 | 中国兽医药品监察所 | 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白 |
| CN110607314B (zh) * | 2019-10-31 | 2022-09-23 | 四川农业大学 | 一种TcdB RBD基因、重组RBD蛋白和应用 |
| CN112442472B (zh) * | 2020-11-30 | 2023-05-26 | 四川大学华西医院 | 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法 |
| CN118613492A (zh) * | 2022-01-30 | 2024-09-06 | 西湖大学 | Tfpi结合多肽及其用途 |
| JP2023134918A (ja) * | 2022-03-15 | 2023-09-28 | 株式会社荏原製作所 | 研磨方法および研磨装置 |
| WO2025029561A2 (en) * | 2023-07-28 | 2025-02-06 | University Of South Florida | Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| AU754270B2 (en) | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
| EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| US7226597B2 (en) | 2002-06-17 | 2007-06-05 | The Board Of Regents Of The University Of Oklahoma | Mutants of Clostridium difficile toxin B and methods of use |
| CN101094594B (zh) | 2003-12-08 | 2012-08-15 | 海布里顿公司 | 通过基于小寡核苷酸的化合物调节免疫刺激性质 |
| PL2857418T3 (pl) | 2004-02-06 | 2017-10-31 | Univ Massachusetts | Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| RU2561673C2 (ru) * | 2006-03-30 | 2015-08-27 | Эмбрекс, Инк. | Способы и композиции для вакцинации домашней птицы |
| MX383424B (es) * | 2009-02-11 | 2025-03-14 | Cedars Sinai Medical Center | Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni |
| CA2752815A1 (en) * | 2009-02-20 | 2010-08-26 | Health Protection Agency | Antibodies to clostridium difficile toxins |
| JP2013503198A (ja) * | 2009-08-27 | 2013-01-31 | シナプティック リサーチ，リミテッド ライアビリティ カンパニー | 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系 |
| US10046040B2 (en) | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| CA2782406A1 (en) | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| CN103957931B (zh) | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| US8431361B2 (en) * | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
| TWI815599B (zh) * | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
-
2013
- 2013-01-24 AR ARP130100216A patent/AR089797A1/es unknown
- 2013-01-25 US US14/374,792 patent/US9388394B2/en active Active
- 2013-01-25 WO PCT/US2013/023189 patent/WO2013112867A1/en not_active Ceased
- 2013-01-25 CA CA2856443A patent/CA2856443A1/en not_active Abandoned
- 2013-01-25 IN IN4187CHN2014 patent/IN2014CN04187A/en unknown
- 2013-01-25 MX MX2014009106A patent/MX351074B/es active IP Right Grant
- 2013-01-25 TW TW102103026A patent/TW201335178A/zh unknown
- 2013-01-25 JP JP2014554865A patent/JP2015506948A/ja active Pending
- 2013-01-25 KR KR1020147020672A patent/KR20140117433A/ko not_active Withdrawn
- 2013-01-25 BR BR112014018432A patent/BR112014018432A8/pt not_active IP Right Cessation
- 2013-01-25 AU AU2013211973A patent/AU2013211973B2/en not_active Ceased
- 2013-01-25 EP EP13740509.8A patent/EP2807186A4/en active Pending
- 2013-01-25 RU RU2014134365A patent/RU2014134365A/ru not_active Application Discontinuation
- 2013-01-25 CN CN201380005667.4A patent/CN104039816B/zh not_active Expired - Fee Related
-
2017
- 2017-02-15 JP JP2017026031A patent/JP2017141226A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2807186A4 (en) | 2016-01-27 |
| BR112014018432A8 (pt) | 2017-07-11 |
| JP2015506948A (ja) | 2015-03-05 |
| JP2017141226A (ja) | 2017-08-17 |
| CN104039816B (zh) | 2018-02-09 |
| TW201335178A (zh) | 2013-09-01 |
| EP2807186A1 (en) | 2014-12-03 |
| IN2014CN04187A (OSRAM) | 2015-07-17 |
| US20150044250A1 (en) | 2015-02-12 |
| CA2856443A1 (en) | 2013-08-01 |
| MX351074B (es) | 2017-09-28 |
| AU2013211973B2 (en) | 2017-10-12 |
| CN104039816A (zh) | 2014-09-10 |
| US9388394B2 (en) | 2016-07-12 |
| AU2013211973A1 (en) | 2014-06-12 |
| MX2014009106A (es) | 2014-11-10 |
| WO2013112867A1 (en) | 2013-08-01 |
| AR089797A1 (es) | 2014-09-17 |
| BR112014018432A2 (OSRAM) | 2017-06-20 |
| KR20140117433A (ko) | 2014-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014134365A (ru) | Вакцины против clostridium difficile, включающие рекомбинантные токсины | |
| Baldauf et al. | Cholera toxin B: one subunit with many pharmaceutical applications | |
| NZ612315A (en) | Compositions for immunising against staphylococcus aureus | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| JP2019525914A5 (OSRAM) | ||
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| EA018765B1 (ru) | Векторы и конструкции для доставки гриппозного антигена | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| Rossetto et al. | The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| RU2019130941A (ru) | РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR | |
| CN102238960B (zh) | 制造疫苗的方法 | |
| WO2022271916A1 (en) | Sars-cov-2 antigen nanoparticles and uses there of | |
| Choi et al. | Potent in vitro and in vivo activity of plantibody specific for Porphyromonas gingivalis FimA | |
| CN104059134B (zh) | 败血性巴氏杆菌毒素重组蛋白及其应用 | |
| Kudyar et al. | Periodontal vaccine: A dream or reality | |
| RU2014124139A (ru) | Подобные коллагену гены шелка | |
| CN102847168B (zh) | 一种预防奶牛乳腺炎的核酸疫苗PV-Fn的设计及其构建 | |
| CA2986025A1 (en) | Methods for immunization against clostridium difficile | |
| RU2017105223A (ru) | Аттенуированный штамм вируса репродуктивно-респираторного синдрома свиней (ррсс) и его возможное применение в средствах для иммунизации | |
| EA201501001A1 (ru) | Вакцина для профилактики и лечения ротавирусной инфекции, содержащая гибридный белок в качестве активного агента (варианты) | |
| KR102675879B1 (ko) | SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도 | |
| NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella | |
| KR102211077B1 (ko) | 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180329 |